#1 Clinical Trials Search in Europe

[89Zr]Bms-986279

This article discusses a clinical trial investigating the use of [89Zr]BMS-986279, also known as Anti-Fucosyl GM1 PET Tracer, in combination with other drugs for the treatment of extensive-stage small cell lung cancer. The study aims to evaluate the safety, effectiveness, and potential benefits of this new combination therapy compared to standard treatment approaches.

Table of Contents

What is [89ZR]BMS-986279?

[89ZR]BMS-986279 is a medical compound being studied for its potential use in patients with extensive-stage small cell lung cancer. It is classified as an Anti-Fucosyl GM1 PET Tracer, which means it’s designed to help doctors see cancer cells more clearly during imaging tests.[1]

Medical Condition

This medication is being investigated for use in extensive-stage small cell lung cancer. Small cell lung cancer is a fast-growing type of lung cancer that often spreads quickly to other parts of the body. The “extensive-stage” means that the cancer has spread beyond one lung or to other parts of the body.[1]

How It Works

[89ZR]BMS-986279 is a PET tracer. PET stands for Positron Emission Tomography, which is an imaging technique used to observe metabolic processes in the body. The tracer is designed to attach to specific cancer cells, making them more visible during a PET scan. This can help doctors better identify the location and extent of cancer in a patient’s body.[1]

Administration

According to the clinical trial information, [89ZR]BMS-986279 is administered through intravenous use. This means it’s given directly into a vein. The dose is measured in MBq (megabecquerels), which is a unit used to measure radioactivity.[1]

Clinical Trial Information

The medication is currently being studied in a clinical trial. Here are some key points about the trial:

  • It’s a Phase 2 trial, which means it’s testing the effectiveness and safety of the medication in a larger group of patients.
  • The trial is comparing different treatment combinations for patients with extensive-stage small cell lung cancer.
  • The main goal is to assess how safe and effective the treatments are, and how long patients live without their cancer getting worse.

It’s important to note that [89ZR]BMS-986279 is being used alongside other cancer treatments in this trial, including chemotherapy drugs (carboplatin and etoposide) and an immunotherapy drug (nivolumab).[1]

Potential Benefits

While the full benefits of [89ZR]BMS-986279 are still being studied, it has the potential to:

  • Improve the accuracy of cancer imaging, helping doctors better understand the extent of a patient’s cancer
  • Aid in monitoring how well treatment is working
  • Potentially lead to more personalized treatment plans for patients with extensive-stage small cell lung cancer

Safety Considerations

As with any medical treatment, safety is a crucial consideration. The clinical trial is carefully monitoring for any side effects or adverse reactions. Some general safety points to keep in mind:

  • This medication is still being studied, so all potential side effects may not be known yet.
  • It’s given in combination with other cancer treatments, which may have their own side effects.
  • The use of radioactive tracers involves exposure to small amounts of radiation, which doctors carefully control and monitor.
  • Patients with certain health conditions or who are pregnant or breastfeeding may not be eligible to receive this treatment.[1]

Remember, [89ZR]BMS-986279 is still in the research phase. If you have extensive-stage small cell lung cancer and are interested in this treatment, talk to your doctor about whether participating in a clinical trial might be right for you.

Aspect Details
Study Type Phase 2 Randomized, Open Label Clinical Trial
Condition Extensive-stage Small Cell Lung Cancer
Intervention [89Zr]BMS-986279 (Anti-Fucosyl GM1 PET Tracer) in combination with other drugs
Primary Objectives Assess safety, tolerability, and progression-free survival
Secondary Objectives Evaluate response rates, survival rates, and immunogenicity
Key Inclusion Criteria ECOG status 0-1, measurable lesions, adequate organ function
Key Exclusion Criteria Pregnancy, certain autoimmune conditions, active pneumonitis
Primary Endpoints Adverse events, progression-free survival
Secondary Endpoints Response rates, survival rates, immunogenicity measures

FAQ

  • What is the purpose of this clinical trial? The main purpose of this trial is to assess the safety and effectiveness of a new combination therapy that includes [89Zr]BMS-986279 along with other drugs for treating extensive-stage small cell lung cancer. The study compares this new approach to a standard treatment regimen.
  • Who can participate in this clinical trial? Participants must have extensive-stage small cell lung cancer, be in good overall health (ECOG performance status 0 or 1), have at least one measurable tumor, and meet specific criteria for organ function. Pregnant or breastfeeding women are not eligible.
  • What treatments are being compared in this study? The study compares two treatment arms: Arm A receives BMS-986012 (which includes [89Zr]BMS-986279) combined with carboplatin, etoposide, and nivolumab, followed by BMS-986012 and nivolumab maintenance. Arm B receives carboplatin, etoposide, and nivolumab, followed by nivolumab maintenance.
  • How is the effectiveness of the treatment measured? The study measures effectiveness through various factors, including progression-free survival (PFS), objective response rate (ORR), time to response (TTR), duration of response (DOR), and overall survival (OS). These are assessed using specific criteria and imaging techniques.
  • What are the potential risks of participating in this trial? As with any clinical trial, there may be risks and side effects. The study closely monitors for adverse events, serious adverse events, and any issues leading to treatment discontinuation. Specific risks are not detailed in the provided information, but participants will be informed of potential risks before joining the study.

Ongoing Clinical Trials on [89Zr]Bms-986279

  • Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Greece Italy The Netherlands Poland Romania +1

Glossary

  • Extensive-stage Small Cell Lung Cancer: An advanced form of lung cancer that has spread beyond the lung where it started and to other parts of the body.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Blinded Independent Central Review (BICR): A method where independent experts review patient data without knowing which treatment the patient received.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Anti-drug Antibodies (ADAs): Antibodies that the body produces against a medication, which can affect its effectiveness or safety.
  • [89Zr]BMS-986279: A radioactive tracer used in PET imaging to help visualize certain types of cancer cells.

References

  1. http://clinicaltrials.eu/trial/study-of-bms-986012-with-carboplatin-etoposide-and-nivolumab-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/